{
    "clinical_study": {
        "@rank": "38569", 
        "acronym": "onset\u00ae 4", 
        "arm_group": [
            {
                "arm_group_label": "FIAsp", 
                "arm_group_type": "Experimental", 
                "description": "The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period"
            }, 
            {
                "arm_group_label": "Insulin Aspart", 
                "arm_group_type": "Active Comparator", 
                "description": "The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe and the United States of America (USA). The aim of this\n      trial is to evaluate compatibility and safety of FIAsp (faster-acting insulin aspart) and\n      insulin aspart (NovoRapid\u00ae) with an external continuous subcutaneous insulin infusion (CSII)\n      system in adult subjects with type 1 diabetes."
        }, 
        "brief_title": "A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, age at least 18 years at the time of signing inform consent\n\n          -  Type 1 diabetes mellitus (diagnosed clinically) for at least 12 months at the time of\n             screening (Visit 1)\n\n          -  Currently treated with insulin aspart, insulin lispro or insulin gluisine for at\n             least 3 months prior to screening (Visit 1)\n\n          -  Using an external CSII system for the previous 6 months prior to screening (Visit 1)\n\n          -  HbA1c (glycosylated haemoglobin) below or equal to 9.0% as assessed by central\n             laboratory\n\n          -  Body Mass Index (BMI) 20.0-35.0 kg/m^2\n\n        Exclusion Criteria:\n\n          -  History of diabetic ketoacidosis (DKA) episodes requiring hospitalization within 6\n             months prior to screening (Visit 1)\n\n          -  History of abscess at the infusion site within 6 months prior to screening (Visit 1)\n\n          -  Hypoglycaemic unawareness as judged by the Investigator or history of severe\n             hypoglycaemic episodes requiring hospitalization within the last 6 months prior to\n             screening (Visit 1)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999322", 
            "org_study_id": "NN1218-3931", 
            "secondary_id": [
                "2013-002233-37", 
                "U1111-1143-2316"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "FIAsp", 
                "description": "Administered subcutaneously (s.c., under the skin). Dose individually adjusted.", 
                "intervention_name": "insulin aspart (FIAsp)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin Aspart", 
                "description": "Administered subcutaneously (s.c., under the skin). Dose individually adjusted.", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30318"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neuss", 
                        "country": "Germany", 
                        "zip": "41460"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A 6-week Randomised, Double-blind, Parallel-group Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of microscopically confirmed episodes of infusion set occlusions", 
            "safety_issue": "No", 
            "time_frame": "During 6 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999322"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of unexplained episodes of hyperglycaemia (confirmed by self-measured plasma glucose (SMPG))", 
                "safety_issue": "No", 
                "time_frame": "During 6 weeks of treatment"
            }, 
            {
                "measure": "Number of episodes of possible infusion set occlusions", 
                "safety_issue": "No", 
                "time_frame": "during 6 weeks of treatment"
            }, 
            {
                "measure": "Number of premature infusion set changes", 
                "safety_issue": "No", 
                "time_frame": "during 6 weeks of treatment"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}